News Detail
Mumbai, 20 March 2025: US pharma major Eli Lilly on Thursday launched the much-awaited diabetes and obesity management drug Mounjaro (tirzepatide) in India, priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for a 5 mg vial.
The drug, usually taken once a we......
View Details
Source : Business Standard
Eli Lilly Mounjaro India
Mounjaro tirzepatide
diabetes drug India
obesity drug India
GLP-1 drugs
weight loss medication
Novo Nordisk Rybelsus
semaglutide India
anti-obesity drug market
diabetes treatment India
CDSCO approval
Indian pharma market
ozempic
Related News
- Impose safeguard duties on medical devices: AiMeD (20-03-2025)
- DCA seizes spurious ‘Montek-LC’ tablets in Secunderabad (20-03-2025)
- Tech Mahindra and NVIDIA Collaborate to Advance Drug Safety with Agentic AI-Powered Pharmacovigilance Solution (20-03-2025)
- US FDA announces recall of Medtronic interventional radiology devices after 17 injuries, 4 deaths (20-03-2025)
- AIIMS forms special committee to monitor adverse drug reactions (19-03-2025)
- Ayush-approved medicines won't require extra safety trials for integrative research: ICMR (19-03-2025)
- USV launches Xenia: Empagliflozin and its combinations for diabetes care in India (19-03-2025)
- Experts Call for Unified Action Against Counterfeiting in Supply Chains (19-03-2025)
- FMCG firms seek separate law for beauty products, current regulations hinder growth (18-03-2025)
- Mumbai: Court rejects discharge pleas of docs booked for prescribing ‘miracle drug’ of Munir Khan (18-03-2025)